ClinicalTrials.gg
CompletedNCT02141672AURA-LVUpdated May 18, 2021Results posted

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

A Phase 2 interventional study of Voclosporin High Dose and Voclosporin Low Dose in Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 86 sites in 20 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Lupus Nephritis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Lupus Nephritis · Russian Federation.

Enrollment
6th of 13
265 · median 147
Started
2014
with 1 other
Phase 2
8 of 13
none open now
Registered
6th of 13
by date
Lead sponsor
2 of 13
Aurinia Pharmaceuticals Inc.

Among the 13 studies in Lupus Nephritis with a site in Russian Federation, this one is the 6th largest by enrollment, is one of 2 that started in 2014, is one of 8 in phase 2, and was the 6th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

None of the 13 studies in Lupus Nephritis with a site in Russian Federation is open now. The open studies under Lupus Nephritis, anywhere →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Lupus Nephritis with a site in Russian Federation as a file.
02

Study summary

To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.

Read the detailed description

Voclosporin is a next generation CNI intended for use in the prevention of organ graft rejection and for the treatment of autoimmune diseases. The aim of the current study is to investigate whether voclosporin added to the standard of care treatment in active LN is able to reduce disease activity, as measured by a reduction in proteinuria. Two doses of voclosporin will be studied and compared in a placebo controlled trial on a background of MMF and corticosteroids. Patients with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria while demonstrating an acceptable safety profile.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

Keywords

  • lupus nephritis
  • calcineurin inhibitors
  • voclosporin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female subjects aged 18 to 75 years.

Diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology criteria.

Kidney within 6 months prior to Screening (Visit 1) with a histologic diagnosis of lupus nephritis (International Society of Nephrology/Renal Pathology Society 2003 classification of lupus nephritis) Classes III, IV-S or IV-G, (A) or (A/C); or Class V, alone or in combination with Class III or IV.

Laboratory evidence of active nephritis at screening, defined as:

  • Class III, IV-S or IV-G: Confirmed proteinuria ≥1,500 mg/24 hours when assessed by 24 hour urine collection, defined by a UPCR of ≥1.5 mg/mg assessed in a first morning void urine specimen (2 samples).
  • Class V (alone or in combination with Class III or IV): Confirmed proteinuria ≥2,000 mg/24 hours when assessed by 24 hour urine collection, defined by a UPCR of ≥2 mg/mg assessed in a first morning void urine specimen (2 samples).

Exclusion criteria

Exclusion Criteria:

Estimated (eGFR) as calculated by the Chronic Kidney Disease Epidemiology Collaboration equation of ≤45 mL/min/1.73 m2.

Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.

A previous kidney transplant or planned transplant within study treatment period.

In the opinion of the Investigator, subject does not require long-term treatment (in addition to ).

Current or medical history of:

  • Pancreatitis or gastrointestinal hemorrhage within 6 months prior to screening.
  • Active unhealed peptic ulcer within 3 months prior to screening. If an ulcer has healed and the subject is on adequate therapy, the subject may be randomized.
  • Congenital or acquired immunodeficiency.
  • drug or alcohol abuse 2 years prior to screening.
  • within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision. Subjects with cervical dysplasia that is cervical intraepithelial neoplasia 1, but have been treated with conization or loop electrosurgical excision procedure, and have had a normal repeat PAP are allowed.
  • Lymphoproliferative disease or previous total lymphoid irradiation.
  • Severe viral infection (such as CMV, , ) within 3 months of screening; or known infection.
  • Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.

Other known clinically significant active medical conditions, such as:

  • Severe cardiovascular disease including congestive heart failure, history of cardiac dysrhythmia or congenital long syndrome.
  • Liver dysfunction (, alanine aminotransferase, or greater than 2.5 times the ) at screening and confirmed before randomization.
  • or asthma requiring oral steroids.
  • Bone marrow insufficiency unrelated to active SLE (according to Investigator judgment) with white blood cell count \<2,500/mm3; \<1.3 x 103/μL; thrombocytopenia ( count \<50,000/mm3).
  • Active bleeding disorders.
  • Current infection requiring IV antibiotics.

Any overlapping condition for which the condition or the treatment of the condition may affect the study assessments or outcomes. Overlapping conditions for which the condition or treatment is not expected to affect assessments or outcomes are not excluded.

Subjects who are pregnant, breast feeding or, if of , not using adequate precautions.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Voclosporin Low Dose

    Voclosporin, oral, 23.7 mg BID

    Drug: Voclosporin Low Dose

  • Experimental
    Voclosporin High Dose

    Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID

    Drug: Voclosporin High Dose

  • Placebo comparator
    Placebo

    Low dose: Voclosporin placebo, oral, 3 capsules BID High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving Complete Renal Remission at 24 Weeks

    Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission.

    Time frame: week 24

Secondary outcomes

  1. Number of Subjects Achieving Complete Renal Remission at 48 Weeks

    Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission.

    Time frame: Week 48

  2. Number of Subjects Achieving Complete Renal Remission at 24 and 48 Weeks in the Presence of Low Dose Steroids

    Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission. Low-dose steroids is defined as use of ≤5 mg prednisone for 8 weeks leading up to the Week 24 visit date or for 12 weeks leading up to the Week 48 visit date.

    Time frame: Weeks 24 and 48

  3. Time to Complete Remission (Number of Weeks)

    Time to Complete Remission is defined as time from first dose of voclosporin/placebo to UPCR ≤ 0.5mg in the absence of rescue medication.

    Time frame: week 48

  4. Time to Sustained Early Complete Remission (Number of Weeks)

    Time to Sustained Complete Remission is defined as time from first dose of voclosporin/placebo to UPCR ≤ 0.5mg occurring at week 24 or earlier and sustained until week 48 in the absence of rescue medication.

    Time frame: week 48

  5. Number of Subjects Achieving Sustained Early Complete Remission

    Sustained early complete remission defined as complete remission that occurred on or before Week 24 and was sustained through Week 48

    Time frame: week 48

  6. Time to Partial Remission (Number of Weeks)

    Time to partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction sustained until week 48 in the absence of rescue medication.

    Time frame: week 48

  7. Number of Subjects Achieving Partial Remission

    Partial remission is defined as a 50% reduction in UPCR from baseline at Week 24 and Week 48.

    Time frame: week 48

  8. Number of Subjects Achieving, and Remaining in, Complete Remission

    Sustained complete remission defined as the first occurrence of complete remission that was sustained through Week 48

    Time frame: week 48

  9. Duration of Complete Remission (Number of Weeks)

    Duration of Complete Remission is defined as time of first occurrence of UPCR ≤ 0.5 mg/mg until the second increase above 0.5 mg/mg (i.e. a single occurrence above 0.5 is permitted) or use of rescue medication.

    Time frame: week 48

  10. Number of Subjects Achieving Partial Renal Remission at 24 and 48 Weeks

    Number of patients with partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction at week 24 or week 48 in the absence of rescue medication.

    Time frame: week 24 and 48

  11. Time to Sustained Partial Remission (Number of Weeks)

    Time to sustained partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction sustained until week 48 in the absence of rescue medication.

    Time frame: week 48

  12. Number of Subjects Achieving Sustained Partial Remission

    Sustained partial remission defined as the first occurrence of partial remission that was sustained through Week 48

    Time frame: week 48

  13. Time to Sustained Early Partial Remission (Number of Weeks)

    Time to sustained early partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction occurring at week 24 or earlier and sustained until week 48 in the absence of rescue medication.

    Time frame: week 48

  14. Number of Subjects Achieving Sustained Early Partial Remission

    Early partial remission defined as partial remission that occurred on or before Week 24 and was sustained through Week 48

    Time frame: week 48

  15. Change From Baseline in UPCR at Weeks 24 and 48

    Change from baseline in urine protein creatinine ratio at weeks 24 and 48

    Time frame: Baseline, Week 24 and Week 48

  16. Change From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score

    The SELENA-SLEDAI assesses disease activity within the last 10 days. Twenty-four items are scored for nine organ systems, and summed to a maximum of 105 points. A score of 6 is considered clinically significant and indicates active disease. For analysis purposes, a score ≥6 was categorized as "high". The 24 items are as follows: seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, and leukopenia.

    Time frame: Baseline, Week 24 and Week 48

07

Results

Posted May 18, 2021

Participant flow

Participant flow — Overall Study
MilestoneVoclosporin Low DoseVoclosporin High DosePlacebo
Started898888
Completed738070
Not completed16818
Withdrew: Adverse event010
Withdrew: Death1021
Withdrew: Lack of efficacy002
Withdrew: Lost to follow-up113
Withdrew: Physician decision125
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject325
Withdrew: Refused to follow-up101

Outcome measures

PrimaryNumber of Subjects Achieving Complete Renal Remission at 24 Weeks

Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission.

Time frame:
week 24
Reported as:
Count of participants · Participants
Number of Subjects Achieving Complete Renal Remission at 24 Weeks
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Achieved response292417
Did not achieve response606471
Statistical analysis
  • Voclosporin Low Dose · Regression, Logistic · p = 0.045 · Odds ratio (or): 2.03 · 95% CI 1.01 to 4.05
  • Voclosporin High Dose · Regression, Logistic · p = 0.204 · Odds ratio (or): 1.59 · 95% CI 0.78 to 3.27
SecondaryNumber of Subjects Achieving Complete Renal Remission at 48 Weeks

Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Subjects Achieving Complete Renal Remission at 48 Weeks
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Achieved response443521
Did not achieve response455367
Statistical analysis
  • Voclosporin Low Dose · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.21 · 95% CI 1.68 to 6.13
  • Voclosporin High Dose · Regression, Logistic · p = 0.026 · Odds ratio (or): 2.1 · 95% CI 1.09 to 4.02
SecondaryNumber of Subjects Achieving Complete Renal Remission at 24 and 48 Weeks in the Presence of Low Dose Steroids

Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission. Low-dose steroids is defined as use of ≤5 mg prednisone for 8 weeks leading up to the Week 24 visit date or for 12 weeks leading up to the Week 48 visit date.

Time frame:
Weeks 24 and 48
Reported as:
Count of participants · Participants
Number of Subjects Achieving Complete Renal Remission at 24 and 48 Weeks in the Presence of Low Dose Steroids
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Achieved response at week 24262317
Achieved response at week 48292618
Statistical analysis
  • Voclosporin Low Dose · Regression, Logistic · p = 0.066 · Odds ratio (or): 1.9 · 95% CI 0.96 to 3.78
  • Voclosporin High Dose · Regression, Logistic · p = 0.162 · Odds ratio (or): 1.64 · 95% CI 0.82 to 3.28
SecondaryTime to Complete Remission (Number of Weeks)

Time to Complete Remission is defined as time from first dose of voclosporin/placebo to UPCR ≤ 0.5mg in the absence of rescue medication.

Time frame:
week 48
Reported as:
Median · weeks
Time to Complete Remission (Number of Weeks)
weeksVoclosporin Low DoseVoclosporin High DosePlacebo
Time to Complete Remission (Number of Weeks)19.7 (16.1 to 36.1)23.4 (13.7 to 33.4)NA (48.1 to NA)
Statistical analysis
  • Voclosporin Low Dose · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.26 · 95% CI 1.45 to 3.51
  • Voclosporin High Dose · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.25 · 95% CI 1.46 to 3.47
SecondaryTime to Sustained Early Complete Remission (Number of Weeks)

Time to Sustained Complete Remission is defined as time from first dose of voclosporin/placebo to UPCR ≤ 0.5mg occurring at week 24 or earlier and sustained until week 48 in the absence of rescue medication.

Time frame:
week 48
Reported as:
Median · weeks
Time to Sustained Early Complete Remission (Number of Weeks)
weeksVoclosporin Low DoseVoclosporin High DosePlacebo
Time to Sustained Early Complete Remission (Number of Weeks)NA (20.0 to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Voclosporin Low Dose · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.89 · 95% CI 1.58 to 5.29
  • Voclosporin High Dose · Regression, Cox · p = <0.248 · Hazard ratio (hr): 1.48 · 95% CI 0.77 to 2.86
SecondaryNumber of Subjects Achieving Sustained Early Complete Remission

Sustained early complete remission defined as complete remission that occurred on or before Week 24 and was sustained through Week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Number of Subjects Achieving Sustained Early Complete Remission
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Number of Subjects Achieving Sustained Early Complete Remission362215
SecondaryTime to Partial Remission (Number of Weeks)

Time to partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction sustained until week 48 in the absence of rescue medication.

Time frame:
week 48
Reported as:
Median · weeks
Time to Partial Remission (Number of Weeks)
weeksVoclosporin Low DoseVoclosporin High DosePlacebo
Time to Partial Remission (Number of Weeks)4.3 (2.6 to 5.9)4.4 (4.1 to 6.1)6.6 (4.6 to 8.6)
Statistical analysis
  • Voclosporin Low Dose · Regression, Cox · p = 0.005 · Hazard ratio (hr): 1.63 · 95% CI 1.16 to 2.27
  • Voclosporin High Dose · Regression, Cox · p = 0.002 · Hazard ratio (hr): 1.74 · 95% CI 1.25 to 2.43
SecondaryNumber of Subjects Achieving Partial Remission

Partial remission is defined as a 50% reduction in UPCR from baseline at Week 24 and Week 48.

Time frame:
week 48
Reported as:
Count of participants · Participants
Number of Subjects Achieving Partial Remission
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Number of Subjects Achieving Partial Remission768267
SecondaryNumber of Subjects Achieving, and Remaining in, Complete Remission

Sustained complete remission defined as the first occurrence of complete remission that was sustained through Week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Number of Subjects Achieving, and Remaining in, Complete Remission
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Number of Participants Achieving Complete Remission576132
Number of Participants Remaining in Complete Remission192810
Number of Participants with Second Increase of UPCR >0.5 mg/mg383322
Statistical analysis
  • Voclosporin Low Dose · Regression, Cox · p = 0.980 · Hazard ratio (hr): 0.99 · 95% CI 0.45 to 2.15
  • Voclosporin High Dose · Regression, Cox · p = 0.118 · Hazard ratio (hr): 1.98 · 95% CI 0.95 to 4.16
SecondaryDuration of Complete Remission (Number of Weeks)

Duration of Complete Remission is defined as time of first occurrence of UPCR ≤ 0.5 mg/mg until the second increase above 0.5 mg/mg (i.e. a single occurrence above 0.5 is permitted) or use of rescue medication.

Time frame:
week 48
Reported as:
Median · weeks
Duration of Complete Remission (Number of Weeks)
weeksVoclosporin Low DoseVoclosporin High DosePlacebo
Duration of Complete Remission (Number of Weeks)49 (42.1 to 49.0)25 (23.3 to NA)NA (26.3 to NA)
SecondaryNumber of Subjects Achieving Partial Renal Remission at 24 and 48 Weeks

Number of patients with partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction at week 24 or week 48 in the absence of rescue medication.

Time frame:
week 24 and 48
Reported as:
Count of participants · Participants
Number of Subjects Achieving Partial Renal Remission at 24 and 48 Weeks
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Achieved partial remission at week 24625843
Achieved partial remission at week 48616342
Statistical analysis
  • Voclosporin Low Dose · Regression, Logistic · p = 0.007 · Odds ratio (or): 2.33 · 95% CI 1.26 to 4.33
  • Voclosporin High Dose · Regression, Logistic · p = 0.024 · Odds ratio (or): 2.03 · 95% CI 1.1 to 3.76
  • Voclosporin Low Dose · Regression, Logistic · p = 0.007 · Odds ratio (or): 2.34 · 95% CI 1.27 to 4.33
  • Voclosporin High Dose · Regression, Logistic · p = 0.002 · Odds ratio (or): 2.68 · 95% CI 1.43 to 5.02
SecondaryTime to Sustained Partial Remission (Number of Weeks)

Time to sustained partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction sustained until week 48 in the absence of rescue medication.

Time frame:
week 48
Reported as:
Median · weeks
Time to Sustained Partial Remission (Number of Weeks)
weeksVoclosporin Low DoseVoclosporin High DosePlacebo
Time to Sustained Partial Remission (Number of Weeks)6.3 (4.0 to 11.9)8.1 (6.1 to 16.6)26.9 (16.1 to NA)
Statistical analysis
  • Voclosporin Low Dose · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.03 · 95% CI 1.36 to 3.03
  • Voclosporin High Dose · Regression, Cox · p = 0.004 · Hazard ratio (hr): 1.81 · 95% CI 1.22 to 2.69
SecondaryNumber of Subjects Achieving Sustained Partial Remission

Sustained partial remission defined as the first occurrence of partial remission that was sustained through Week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Number of Subjects Achieving Sustained Partial Remission
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Number of Subjects Achieving Sustained Partial Remission616342
SecondaryTime to Sustained Early Partial Remission (Number of Weeks)

Time to sustained early partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction occurring at week 24 or earlier and sustained until week 48 in the absence of rescue medication.

Time frame:
week 48
Reported as:
Median · weeks
Time to Sustained Early Partial Remission (Number of Weeks)
weeksVoclosporin Low DoseVoclosporin High DosePlacebo
Time to Sustained Early Partial Remission (Number of Weeks)6.3 (4.0 to 11.9)8.1 (6.1 to 16.6)NA (16.1 to NA)
Statistical analysis
  • Voclosporin Low Dose · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.21 · 95% CI 1.45 to 3.36
  • Voclosporin High Dose · Regression, Cox · p = 0.004 · Hazard ratio (hr): 1.87 · 95% CI 1.23 to 2.84
SecondaryNumber of Subjects Achieving Sustained Early Partial Remission

Early partial remission defined as partial remission that occurred on or before Week 24 and was sustained through Week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Number of Subjects Achieving Sustained Early Partial Remission
ParticipantsVoclosporin Low DoseVoclosporin High DosePlacebo
Number of Subjects Achieving Sustained Early Partial Remission605836
SecondaryChange From Baseline in UPCR at Weeks 24 and 48

Change from baseline in urine protein creatinine ratio at weeks 24 and 48

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · mg/mg
Change From Baseline in UPCR at Weeks 24 and 48
mg/mgVoclosporin Low DoseVoclosporin High DosePlacebo
Baseline UPCR5.161 ± 4.1514.476 ± 3.0294.433 ± 3.58
week 24 UPCR1.021 ± 1.23691.356 ± 1.52042.266 ± 2.8534
CFB at week 24-3.769 ± 3.351-2.792 ± 2.6207-2.216 ± 3.9284
week 48 UPCR0.689 ± 0.91721.101 ± 1.38351.763 ± 1.9927
CFB at week 48-3.998 ± 3.4208-2.993 ± 2.6608-2.384 ± 3.454
SecondaryChange From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score

The SELENA-SLEDAI assesses disease activity within the last 10 days. Twenty-four items are scored for nine organ systems, and summed to a maximum of 105 points. A score of 6 is considered clinically significant and indicates active disease. For analysis purposes, a score ≥6 was categorized as "high". The 24 items are as follows: seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, and leukopenia.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · score on a scale
Change From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score
score on a scaleVoclosporin Low DoseVoclosporin High DosePlacebo
SELENA-SLEDAI Score at baseline12.7 ± 6.3713.9 ± 6.5112.9 ± 6.57
SELENA-SLEDAI Score at week 246.2 ± 4.536.5 ± 5.428.8 ± 5.43
SELENA-SLEDAI Score change from baseline at week 24-6.3 ± 5.86-7.1 ± 7.41-4.5 ± 7.09
SELENA-SLEDAI Score at week 484.7 ± 5.065.3 ± 3.977.8 ± 5.93
SELENA-SLEDAI Score Change from baseline at week 48-7.9 ± 6.39-8.3 ± 6.93-5.3 ± 6.85

Adverse events

Collected over Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voclosporin Low Dose10/89 (11.2%)25/89 (28.1%)82/89 (92.1%)
Voclosporin High Dose2/88 (2.3%)22/88 (25%)85/88 (96.6%)
Placebo1/88 (1.1%)14/88 (15.9%)75/88 (85.2%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventVoclosporin Low DoseVoclosporin High DosePlacebo
PneumoniaInfections and infestations5/893/882/88
Renal Failure AcuteRenal and urinary disorders4/891/880/88
GastroenteritisInfections and infestations1/892/881/88
SepsisInfections and infestations1/892/880/88
Posterior Reversible Encephalitis SyndromeNervous system disorders2/892/880/88
Systemic Lupus ErythematosusMusculoskeletal and connective tissue disorders1/892/882/88
HypertensionVascular disorders2/892/880/88
Urinary Tract InfectionInfections and infestations2/891/880/88
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders2/891/880/88
Acute Respiratory Distress SyndromeRespiratory, thoracic and mediastinal disorders2/890/880/88
Most frequent other events
Showing 10 of 36
Most frequent other events
EventVoclosporin Low DoseVoclosporin High DosePlacebo
Glomerular Filtration Rate DecreasedInvestigations27/8927/8812/88
Upper Respiratory Tract InfectionInfections and infestations12/8918/8814/88
DiarrhoeaGastrointestinal disorders16/8914/8814/88
NauseaGastrointestinal disorders16/8911/887/88
CoughRespiratory, thoracic and mediastinal disorders16/895/883/88
HeadacheNervous system disorders10/8915/8811/88
HypertensionVascular disorders15/8914/888/88
VomitingGastrointestinal disorders15/899/8810/88
AnaemiaBlood and lymphatic system disorders13/8914/887/88
HypokalaemiaMetabolism and nutrition disorders12/8912/889/88

Baseline characteristics

Age, Continuous
Age, Continuous(years)Voclosporin Low DoseVoclosporin High DosePlaceboTotal
Mean31.4 ± 11.7830.6 ± 9.5933.1 ± 10.0331.7 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)Voclosporin Low DoseVoclosporin High DosePlaceboTotal
Female768173230
Male1371535
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Voclosporin Low DoseVoclosporin High DosePlaceboTotal
Hispanic or Latino9131335
Not Hispanic or Latino807575230
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Voclosporin Low DoseVoclosporin High DosePlaceboTotal
American Indian or Alaska Native4239
Asian524436132
Native Hawaiian or Other Pacific Islander0011
Black or African American36514
White303642108
More than one race0000
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)Voclosporin Low DoseVoclosporin High DosePlaceboTotal
United States510621
Bangladesh17161346
Belarus18413
Bulgaria2125
Ecuador2125
Georgia1135
Guatemala26311
Hong Kong0011
South Korea3227
Mexico33814
Philippines20131043
Poland2024
Russia1091332
Serbia41712
Singapore0101
Spain1001
Sri Lanka54514
Taiwan2125
Thailand56213
Ukraine45312
Lupus Nephritis history
Lupus Nephritis history(years)Voclosporin Low DoseVoclosporin High DosePlaceboTotal
Years since diagnosis of LN (years)4.2 ± 5.143.2 ± 4.363.5 ± 4.033.7 ± 4.54
Years since first significant proteinuria (years)4.5 ± 5.533.3 ± 4.223.6 ± 4.063.8 ± 4.66
Lupus Nephritis history - Baseline UPCR
Lupus Nephritis history - Baseline UPCR(mg/mg)Voclosporin Low DoseVoclosporin High DosePlaceboTotal
Median5.16 ± 4.154.48 ± 3.034.43 ± 3.584.69 ± 3.6
Lupus Nephritis history - Baseline eGFR
Lupus Nephritis history - Baseline eGFR(mL/min/1.73 m2)Voclosporin Low DoseVoclosporin High DosePlaceboTotal
Mean95.3 ± 28.4104 ± 27.3100.2 ± 27.0599.8 ± 27.71
08

Study locations

86 sites
  • AURA-LV Site
    Los Angeles, California 90095, United States
  • AURA-LV Site
    Palo Alto, California 94305, United States
  • AURA-LV Site
    Gainesville, Florida 32610, United States
  • AURA-LV Site
    Miami, Florida 33165, United States
  • AURA-LV Site
    Farmington Hills, Michigan 48334, United States
  • AURA-LV Site
    Brooklyn, New York 11203, United States
  • AURA-LV Site
    New York, New York 10016, United States
  • AURA-LV Site
    Chapel Hill, North Carolina 27599, United States
  • AURA-LV Site
    Charlotte, North Carolina 28204, United States
  • AURA-LV Site
    Columbus, Ohio 43210, United States
  • AURA-LV Site
    Hershey, Pennsylvania 17033, United States
  • AURA-LV Site
    Chattanooga, Tennessee 37408, United States
  • AURA-LV Site
    Dallas, Texas 75390, United States
  • AURA-LV Site
    Houston, Texas 77030, United States
  • AURA-LV Site
    Dhaka, 1207, Bangladesh
  • AURA-LV Site
    Dhaka, Bangladesh
  • AURA-LV Site
    Minsk, 220037, Belarus
  • AURA-LV Site
    Minsk, 220116, Belarus
  • AURA-LV Site
    Minsk, 223040, Belarus
  • AURA-LV Site
    Vitebsk, 210037, Belarus
  • AURA-L Site
    Plovdiv, 4001, Bulgaria
  • AURA-LV Site
    Sofia, 1431, Bulgaria
  • AURA-LV Site
    Sofia, 1527, Bulgaria
  • AURA-LV Site
    Varna, 9010, Bulgaria
  • AURA-LV Site
    Hong Kong, China
  • AURA-LV Site
    Guayaquil, Ecuador
  • AURA-LV Site
    Quito, Ecuador
  • AURA-LV Site
    Tbilisi, 0144, Georgia
  • AURA-LV Site
    Tbilisi, 0186, Georgia
  • AURA-LV Site
    Guatemala City, Guatemala
  • AURA-LV Site
    Busan, 602-739, Korea, Republic of
  • AURA -LV Site
    Daegu, 705-718, Korea, Republic of
  • AURA-LV Site
    Seoul, 110-744, Korea, Republic of
  • AURA-LV Site
    Seoul, 158-710, Korea, Republic of
  • AURA-LV Site
    Wonju, 220-701, Korea, Republic of
  • AURA-LV Site
    Guadalajara, 44280, Mexico
  • AURA-LV Site
    Mexicali, 21100, Mexico
  • AURA-LV Site
    Oaxaca, Mexico
  • AURA-LV Site
    Tlalpan, 14080, Mexico
  • AURA-LV Site
    Tlalpan, Mexico
  • AURA-LV Site
    Angeles City, 2009, Philippines
  • AURA-LV Site
    Batangas, 4217, Philippines
  • AURA-LV Site
    Cebu city, 6000, Philippines
  • AURA-LV Site
    Davao City, 8000, Philippines
  • AURA-LV Site
    Manila, 10000, Philippines
  • AURA-LV Site
    Manila, 1000, Philippines
  • AURA-LV Site
    Manila, 1003, Philippines
  • AURA-LV Site
    Quezon City, 1102, Philippines
  • AURA-LV Site
    Katowice, 40-027, Poland
  • AURA-LV Site
    Radom, 26-610, Poland
  • AURA-LV Site
    Warsaw, 01-141, Poland
  • AURA-LV Site
    Wroclaw, 50-556, Poland
  • AURA-LV Site
    Kazan, 420012, Russian Federation
  • AURA-LV Site
    Kemerovo, 650066, Russian Federation
  • AURA-LV Site
    Kemerovo, 65009, Russian Federation
  • AURA-LV Site
    Moscow, 111539, Russian Federation
  • AURA-LV Site
    Moscow, 119435, Russian Federation
  • AURA-LV Site
    Omsk, 644111, Russian Federation
  • AURA-LV Site
    Orenburg, 460018, Russian Federation
  • AURA-LV Site
    Petrozavodsk, 185019, Russian Federation
  • AURA-LV Site
    Rostov-on-Don, 344022, Russian Federation
  • AURA-LV Site
    Saratov, 410053, Russian Federation
  • AURA-LV Site
    St. Petersburg, 191015, Russian Federation
  • AURA-LV Site
    St. Petersburg, 197022, Russian Federation
  • AURA-LV Site
    St. Petersburg, 197110, Russian Federation
  • AURA-LV Site
    Togliatti, 445009, Russian Federation
  • AURA-LV Site
    Yaroslavl, 150062, Russian Federation
  • AURA-LV Site
    Belgrade, 11000, Serbia
  • AURA-LV Site
    Nis, 18000, Serbia
  • AURA-LV Site
    Singapore, 169608, Singapore
  • AURA-LV Site
    Singapore, 529889, Singapore
  • AURA-LV Site
    Barcelona, Spain
  • AURA-LV
    Madrid, 28034, Spain
  • AURA-LV Site
    Colombo, Sri Lanka
  • AUR-LV Site
    Kandy, 20000, Sri Lanka
  • AURA-LV Site
    Nugegoda, 10100, Sri Lanka
  • AURA-LV Site
    Ragama, Sri Lanka
  • AURA-LV Site
    Kaohsiung City, 83301, Taiwan
  • AURA-LV Site
    Taoyuan City, 333, Taiwan
  • AURA-LV Site
    Bangkok, 10400, Thailand
  • AURA-LV Site
    Chiang Mai, 50200, Thailand
  • AURA-LV Site
    Kharkiv, 61103, Ukraine
  • AURA-LV Site
    Kyiv, 02125, Ukraine
  • AURA-LV Site
    Kyiv, 04050, Ukraine
  • AURA-LV Site
    Lutsk, 43005, Ukraine
  • AURA-LV Site
    Zaporizhzhya, 69600, Ukraine
09

References and documents

Publications

  • Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460. PubMed 22087680 ↗
  • Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15. PubMed 19369404 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Jul 2016 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2014
First posted
May 19, 2014
Start
Jun 2014
Primary completionActual
Jul 2016
CompletionActual
Jan 2017
Results first posted
May 18, 2021
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02141672
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
May 19, 2014
Start date
Jun 2014
Primary completion
Jul 2016
Completion
Jan 2017
Results posted
May 18, 2021
Last update
May 18, 2021

Study contacts

Mary Anne Dooley, MD, MPH
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion